Date du début: 1 juin 2015,
Date de fin: 30 nov. 2020,
The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi ...
Date du début: 1 mars 2014,
Date de fin: 28 févr. 2018,
This project aims to unite global efforts to target the highly druggable class of enzymes called cyclic nucleotide phosphodiesterases (PDEs) in the fight for neglected parasitic diseases (NPD). It will establish a drug discovery platform, PDE4NPD, that combines phenotypic screening with efficient target-centric drug discovery, including target validation, various strategies for compound screening, ...
Date du début: 1 janv. 2013,
Date de fin: 31 déc. 2017,
The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Date du début: 1 nov. 2012,
Date de fin: 31 oct. 2017,
There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Date du début: 1 janv. 2010,
Date de fin: 30 nov. 2016,
Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Date du début: 1 mai 2009,
Date de fin: 30 avr. 2014,
"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Un expert peut vous aider dans toutes les phases de développement de votre projet
Bonjour, vous êtes sur la plateforme Région Sud Provence-Alpes-Côte d’Azur dédiée aux programmes thématiques et de coopération territoriale. Une équipe d’experts vous accompagne dans vos recherches de financements.
Contactez la Région Sud Provence-Alpes-Côte d'Azur
Vous pouvez nous écrire en Anglais, Français et Italien